Incorporating Anti Mullerian Hormone as a Diagnostic Marker can Enhance PCOS Diagnosis.

The Rotterdam criteria are widely used to diagnose polycystic ovary syndrome (PCOS), and Transvaginal ultrasound (TVUS) plays an important part. The identifying features of PCOS are the presence of polycystic ovarian morphology (PCOM) and Anti-Mullerian hormone (AMH) levels. 

A study focused on assessing the diagnostic utility of serum-AMH in identifying polycystic ovary syndrome (PCOS) and its potential as a substitute for PCOM – in the Rotterdam criteria. The researchers also explored the relationship between AMH levels and hyperandrogenism in PCOS patients.

This study was conducted among Indian women in the age range 18-40 years who had no significant medical history from 2020-2022. The study utilized serum-AMH levels measured via a sensitive Gen-II ELISA assay. 

The results showed significantly higher AMH levels in individuals with PCOS compared to controls. 

It was concluded that although AMH alone may not be a definitive PCOS diagnostic marker, incorporating it into the existing Rotterdam criteria could enhance the accuracy of PCOS diagnosis. AMH offers objectivity and quantitative assessment, making it a promising addition to the diagnostic criteria, particularly as a replacement for PCOM. Further research is recommended to support its use as a diagnostic tool for PCOS.

Source: Pandey U, Gupta N, Jain S, Singh S K. Indian J Obstet Gynecol Res 2023;10(3):294-298